A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Key facts

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Intervention

AL2846 Capsules(drug)

Enrollment

144 enrolled

Eligibility

18-75 years · All sexes

Timeline

2025 – 2028

Study locations (30)

• The Second Hospital Of Anhui Medical University, Hefei, Anhui, China
• cancer hospital Chinese academy of medical sciences, Beijing, Beijing Municipality, China
• The Southwest Hospital of Amu, Chongqing, Chongqing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
• Affiliated Hospital of Guilin Medical University, Gui'lin, Guangxi, China
• The Second Affiliated Hospital Of GXUST, Liuchow, Guangxi, China
• The First Affiliated Hospital of Hainan Medical University, Hainan, Haikou, China
• CangZhou Center Hospital, Cangzhou, Hebei, China
• Harbin Medical University cancer hospital, Harbin, Heilongjiang, China
• Henan Cancer Hospital, Zhengzhou, Henan, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
• Hunan Cancer Hospital, Changsha, Hunan, China
• Nanjing First Hospital, Nanjing, Jiangsu, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Differentiated thyroid carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07068542
  Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
  Zhejiang Provincial People's Hospital
• RECRUITINGPHASE2NCT06440850
  Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06359847
  Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
  Beijing Scitech-Mq Pharmaceuticals Limited
• ACTIVE NOT RECRUITINGNANCT06422702
  The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer
  Harbin Medical University
• RECRUITINGNCT05994365
  Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• ACTIVE NOT RECRUITINGNCT04970134
  Spanish Study for Molecular Characterization of Thyroid Carcinoma
  Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
• ACTIVE NOT RECRUITINGPHASE2NCT05007093
  Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
  Yansong Lin
• ACTIVE NOT RECRUITINGNCT02185560
  Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
  Bayer

See all trials for Differentiated thyroid carcinoma →